

AIMING FOR THE OPTIMAL CARBONATE PRESCRIPTION FOR MAINTENANCE HEMODIALYSIS THERAPY IN END – STAGE RENAL DISEASE

I. Petrou, A. Bozikas, I. Kiriakoutzik, T. Touroutzis, E. Kitoukidi, P. Pisanidou, N. Georgilas, P. Pangidis, S. Spaia Nephrology Department – Hemodialysis Unit, General Hospital of Thessaloniki "Agios Pavlos", Thessaloniki, Greece

OBJECTIVES

Both acidaemia and alkalaemia can be associated with adverse consequences and maintenance of acid – base balance remains an important aspect of renal replacent therapies <u>l</u>

Current K/DOQI guidelines recommend predialysis or stabilised serum bicarnbonate levels should be maintened at or above 22 mmol/L²

Normalization of the predialysis or stabilized serum bicarbonate concentration can be achieved by higher basic anion concentrations in the dialysate and/or by oral supplementation with bicarbonate salts

An oral dose of sodium bicarbonate, approximately 2 to 4 g/d or 25 to 50 mEq/d, can be used to effectively increase serum bicarbonate concentrations 3.4.5

We compared the effect of higher doses of bicarbonate based dialysate to a standard bicarbonate bath plus oral bicarbonate therapy

METHODS

Patients	Sex	Mean Age (years)	HD Duration (months)
60	31 male 29 female	72±10	59±70

60 stable HD patients were evaluated according to their predialysis acid – base status both before the 1st and the 2nd session of the week with a standard bicarbonate based dialysate of 35 mEq/l, Ca: 1.5 mmol/l and Glu: 100 mg/dl

Those who presented with predialysis HCO3⁻ levels of less than 22 mEq/l were assigned to dialysis against dialysis bath with increased bicarbonate levels (+2 mEq/l) for two weeks (period A) and subsequently to dialysis with the standard dialysate bath plus addition of daily oral sodium bicarbonate at a dose of 5 gr per day (t.i.d.) for 2 more weeks (period B)

Records of pre and post dialysis acid base status after each study period, along with laboratory tests and evaluation of different parameters (residual diuresis, UF, BMI, BP, dialysis via central catheter, and on – line HDF) were recorded

RESULTS

Predialysis acid base profile didn't present robust differences, between the 1st and 2nd dialysis session. In this study, predialysis profile was not correlated with residual diuresis, UF, BMI, BP, dialysis via central catheter, and online HDF In 25 patients predialysis pH was < 7.35, while 42 patients presented predialysis

In 25 patients predialysis pH was < 7.35, while 42 patients presented predialysis HCO3 $^{-}$ < 22 mEq/L

Those patients were of younger age (70 vs. 78 years old, p < 0.05)

However, 18 patients had pH >7.45 after dialysis session

Overall 25 patients accepted to participate to the subsequent interventional period During period A (HCO3⁻ +2 mEq/l) postdialysis serum bicarbonate levels were significantly increased (p<0.05)

During period B the postdialysis increment of the serum bicarbonates was less prominent

Patients appeared with predialysis levels of HCO3⁻ in accordance with guidelines, only on period B, after 2 weeks of oral bicarbonate

On the contrary, predialysis levels of serum bicarbonates during period A, were significantly lower than period B

Interdialytic weight was similar, between the two study periods. Three patients could not tolerate symptoms of alkalemia in period A and suffered headaches and muscle cramps

Moreover, several patients resented the frequency and the taste of oral bicarbonate

Values prior to 1st and 2nd dialysis session 2nd HD 1st HD pН 7.34 ± 0.64 7.34 ± 0.05 ns HCO₃ (mmol/L) 20.5 ± 2.4 21.3 ± 1.8 ns BE (mmol/L) -4.1 ± 3 -3.5 ± 2 ns pCO₂ (mmHg) 39.2 ± 6.8 40.6 ± 5.7 ns Lactate (mmol/L) 1.1 ± 0.4 1.3 ± 0.4 ns

 Comparison of pre HD vs post HD on Period A

 pre HD
 post HD
 p


 pH
 7.34 ± 0.05 7.43 ± 0.04 0.001

 HCO3- (mmol/L)
 21.3 ± 1.8 25.6 ± 1.3 0.001

 BE (mmol/L)
 -3.5 ± 2 -1.8 ± 1.5 0.001

 pCO₂ (mmHg)
 40.6 ± 5.7 38.9 ± 4.2 0.065

 Lac (mmol/L)
 1.3 ± 0.4 0.9 ± 0.4 0.001



	Period A	Period B	P
HCO3⁻ predialysis	21.51±2.5	23.02±2.8	0.03
HCO3- post dialysis	27.6±1,7	26.4±1	0.03
pH predialysis	7.36±0.05	7.36±0.05	ns

DISCUSSION – CONCLUSIONS

Our current thrice – weekly HD paradigm necessitates a trade – off of potentially large fluctuations in serum bicarbonate over short periods of time to assure a net physiological acid – base mass balance. This rapid delivery of large quantities of base is obviously non – physiological and not without potential consequences. Increasing bicarbonate dialysis bath results in more prominent postdialysis alkalemia, and still it is not sufficient to maintain acid – base balance in the interdialytic period Indeed, this study shows that the impact of conventional dialysate bicarbonate concentrations of 35 mEq/L results in a considerable degree of **predialysis acidemia**, followed by significant increase of alkali burden, exposing patients to higher mortality risk. Recently, it has been demonstrated, that low blood levels of bicarbonate may indicate an elevated risk of premature death in generally healthy older individuals. 6.7

These findings suggest that the use of this blood marker is an important health indicator and that future studies should examine the potential of increasing bicarbonate levels to prolong life.

The addition of oral bicarbonates on a daily basis could neutralize a part of the daily acid load, avoid pre dialysis acideamia and excessive post dialysis alkalemia.

This hypothesis was evaluated in our short term study and it was confirmed that **oral bicarbonate therapy** at a dose of 5 gr per day proved to be **a more physiological approach** and resulted in a balanced acid base status, avoiding excessive postdialysis alkalemia. However, compliance in this study was achieved mainly because of the short term design of period B, since patients were complaining of the additional "medication" in their daily routine as well as the unusual taste. In those patients we have currently reduced the dose of oral bicarbonate and adjusted the dialysate bath.

In conclusion, the ideal scenario for optimal acid – base management in MHD patients includes a multifaceted approach of oral and individualized delivery of bicarbonate rather than a unit – wide prescription that is infrequently changed.

REFERENCES

- Saikumar JH, Kovesdy CP
 Bicarbonate Therapy in End-Stage Renal Disease:
 Current Practice Trends and Implications.
 Semin Dial. 2015 Jul Aug; 28(4): 370-6. doi:
 10.1111/sdi.12373. Epub 2015 Apr 6.
- K/DOQI NKF
 Clinical Practice Guidelines for nutrition in chronic renal failure. Management of Acid Base status.
 Am. J Kidney Dis 35: 1-140, 2000
- Brady JP, Hasbargen JA
 Correction of metabolic acidosis and its effect on albumin in chronic hemodialysis patients.
- Am J Kidney Dis 31:35-40, 1998

 4. Harris DC, Yuill E, Chesher DW

 Correcting acidosis in hemodialysis:

 Effect on phosphate clearance and calcification risk.
- J Am Soc Nephrol 6: 1607-1612, 1995

 5. Kooman JP, Deutz NE, Zijlmans P, van dA, Gerlag PG, van HP, Leunissen KM
- The influence of bicarbonate supplementation on plasma levels of branched-chain amino acids in haemodialysis patients with metabolic acidosis.

 Nephrol Dial Transplant 12: 2397-2401, 1997
- 6. Wu D, Shinaberger C, Regidor D, McAllister C, Kopple J, Kalantar-Zadeh K
 Association between Serum Bicarbonate and Death in Hemodialysis Patients: Is It Better to Be Acidotic or
- Hemodialysis Patients: Is It Better to Be Acidotic or Alkalotic? Clinical Journal of the American Society of Nephrology (CJASN), doi: 10.2215/CJN.00010505 CJASN
- January 2006 vol. 1 no. 1 70-78

 7. Mayor S

 Low blood levels of bicarbonate are linked to premature
- Low blood levels of bicarbonate are linked to prematus death in healthy older people, study shows.

 BMJ 2016 Jan 14;352:i172. doi: 10.1136 bmj.i172



